Completed

rTMSTranscranial Magnetic Stimulation for Cognitive and Mobility Improvement in Parkinson's Disease

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
Study Aim

This study aims to evaluate the effects of Transcranial Magnetic Stimulation on improving cognitive abilities and mobility in individuals living with Parkinson's Disease.

What is being tested

Active Repetitive Transcranial Magnetic Stimulation (rTMS)

+ Sham Repetitive Transcranial Magnetic Stimulation

Device
Who is being recruted

Synucleinopathies+13

+ Basal Ganglia Diseases

+ Mental Disorders

Over 65 Years
+8 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: November 2022
See protocol details

Summary

Principal SponsorUniversity of Gaziantep
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: November 15, 2022

Actual date on which the first participant was enrolled.

Parkinson's disease can cause issues with thinking, walking, and handling multiple tasks at once, leading to mobility problems, increased risk of falls, and loss of independence. This study explores if repetitive transcranial magnetic stimulation (rTMS), a non-invasive brain stimulation technique, can improve cognitive function and mobility during single and multiple tasks in people with Parkinson's disease. The focus is on stimulating a specific brain area, the left dorsolateral prefrontal cortex, to enhance cognitive abilities and motor functions. Participants in this study undergo a two-week program, where they receive either active rTMS or a placebo stimulation. Before and after this intervention, participants complete standard cognitive and mobility assessments. These tests help determine if rTMS brings about any changes in cognitive and mobility performance. The study aims to provide initial evidence on whether stimulating a brain region responsible for executive control can support motor-cognitive functions in individuals with Parkinson's disease.

Official TitleThe Effect of Repetitive Transcranial Magnetic Stimulation on Dual-task Performance in Patients With Parkinson's Disease
NCT07310238
Principal SponsorUniversity of Gaziantep
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

41 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

SynucleinopathiesBasal Ganglia DiseasesMental DisordersBrain DiseasesCentral Nervous System DiseasesCognition DisordersMovement DisordersNervous System DiseasesNeurologic ManifestationsParkinson DiseaseSigns and SymptomsPathological Conditions, Signs and SymptomsNeurodegenerative DiseasesNeurocognitive DisordersGait Disorders, NeurologicParkinsonian Disorders

Criteria

4 inclusion criteria required to participate
Clinical diagnosis of Parkinson's disease.
Currently receiving dopaminergic therapy.
Ability to stand independently for at least 30 seconds.
Age 65 years or older.
4 exclusion criteria prevent from participating
Any contraindication to transcranial magnetic stimulation (e.g., metal implants in the head, history of seizures).
Inability to walk for 2 minutes without a walking aid.
Musculoskeletal injury or structural abnormality that could affect mobility assessment.
Presence of another neurological disease.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Participants receive repetitive transcranial magnetic stimulation (rTMS) applied to the left dorsolateral prefrontal cortex at 5 Hz, 120% of the resting motor threshold, for 10 sessions over two weeks.

Group II

Sham
Participants receive sham stimulation using the same coil positioning and session structure as the active rTMS group, but without active magnetic output. Sham sessions match the schedule and duration of the intervention arm.

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Gaziantep University

Gaziantep, Turkey (Türkiye)Open Gaziantep University in Google Maps
CompletedOne Study Center